Why Lexicon Pharmaceuticals, Inc.’s (LXRX) Stock Is Down 6.73%
As of Thursday, August 06, Lexicon Pharmaceuticals, Inc.’s LXRX share price has dipped by 6.73%, which has investors questioning if this is right time to buy.Michael Rose
Stock Evaluator: Lexicon Pharmaceuticals, Inc. (LXRX)
Lexicon Pharmaceuticals, Inc. LXRX
$2.41
-0.01
-0.41%
August 19, 2026 4:00:00 PM
EST
Volume: 1,776,085
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Commentary & Analysis
Why Lexicon Pharmaceuticals, Inc.’s (LXRX) Stock Is Down 5.06%
As of Wednesday, July 08, Lexicon Pharmaceuticals, Inc.’s LXRX share price has dipped by 5.06%, which has investors questioning if this is right time to buy.Michael Rose
Why Lexicon Pharmaceuticals, Inc.’s (LXRX) Stock Is Up 5.46%
As of Friday, June 26, Lexicon Pharmaceuticals, Inc.’s LXRX share price has surged by 5.46%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Lexicon Pharmaceuticals, Inc.’s (LXRX) Stock Is Up 5.38%
As of Wednesday, June 17, Lexicon Pharmaceuticals, Inc.’s LXRX share price has surged by 5.38%, which has investors questioning if this is right time to sell.Michael Rose
Why Lexicon Pharmaceuticals, Inc.’s (LXRX) Stock Is Up 6.49%
As of Thursday, June 04, Lexicon Pharmaceuticals, Inc.’s LXRX share price has surged by 6.49%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | LXRX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $967.8 | $618.0 | 44% |
|
| Shares Out (Mil) | 437.7 | 44.8 | 87% |
|
| Institutional Ownership | 96.0% | 85.3% | 69% |
|
| Float (Mil) | 219.0 | 47.4 | 75% |
|
| Beta | 1.04 | 0.70 | 63% |
|
| Avg Daily Volume (000s) | 2,839 | 390 | 87% |
|
| Price Change (52-week) |
87.5% | 68.6% | 89% |
|
| Growth | LXRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 15.7% | 6.7% | 74% |
|
| Net Income (5yr) | 3.0% | (1.6%) | 44% |
|
| EPS (5yr) | 23.4% | 14.9% | 73 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.0%) | (14.9%) | 52% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 4 | |
| Current EPS | ($0.053) | ($0.166) | ($0.191) | |
| Month Ago EPS | ($0.060) | ($0.159) | ($0.206) | |
| # Rev Up | 1 | 0 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.060) | ($0.159) | ($0.206) | |
| Year/Year Chg | (27.4%) | 19.4% | (36.7%) | |
| Financials | LXRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $42 | $291 | 18% |
|
| Net Income (TTM) (Mil) | ($61) | ($11) | 15% |
|
| EPS (TTM) | ($0.156) | ($0.700) | 35% |
|
| Operating Cash Flow (TTM) (Mil) | ($65) | ($6) | 8% |
|
| Net Cash Flow (TTM) (Mil) | ($9) | $5 | 30% |
|
| Long-Term Debt (Q1) (Mil) | $58 | $6 | 40% |
|
| Enterprise Value (Q1) (Mil) | $968 | $450 | 40% |
|
| Valuation | LXRX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 5.58 | 2.78 | 80% |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | LXRX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 86.0% | 67.0% | 92% |
|
| Net Margin | (147.4%) | (2.3%) | 6% |
|
| ROA | (25.7%) | (22.4%) | 18% |
|
| ROE | (40.2%) | (20.2%) | 17% |
|
| Liabilities to Assets | 30.2% | 32.2% | 22% |
|
| F-Score | 2 | 3 | 7% |
|
Lexicon Pharmaceuticals, Inc. did not pass any screens on 8/20/2026.
